[go: up one dir, main page]

DK3275438T3 - Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko - Google Patents

Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko Download PDF

Info

Publication number
DK3275438T3
DK3275438T3 DK17183806.3T DK17183806T DK3275438T3 DK 3275438 T3 DK3275438 T3 DK 3275438T3 DK 17183806 T DK17183806 T DK 17183806T DK 3275438 T3 DK3275438 T3 DK 3275438T3
Authority
DK
Denmark
Prior art keywords
dyslipidemic
disciplined
populations
population
methods
Prior art date
Application number
DK17183806.3T
Other languages
English (en)
Inventor
Ryu Oshima
Gary Gordon
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59506076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3275438(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Co filed Critical Kowa Co
Application granted granted Critical
Publication of DK3275438T3 publication Critical patent/DK3275438T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17183806.3T 2016-07-29 2017-07-28 Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko DK3275438T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662368245P 2016-07-29 2016-07-29
US201762462574P 2017-02-23 2017-02-23

Publications (1)

Publication Number Publication Date
DK3275438T3 true DK3275438T3 (da) 2021-01-18

Family

ID=59506076

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17183806.3T DK3275438T3 (da) 2016-07-29 2017-07-28 Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko

Country Status (13)

Country Link
US (5) US10869859B2 (da)
EP (2) EP3275438B2 (da)
CY (1) CY1123833T1 (da)
DK (1) DK3275438T3 (da)
ES (1) ES2847168T5 (da)
HR (1) HRP20210082T1 (da)
HU (1) HUE053081T2 (da)
LT (1) LT3275438T (da)
PL (1) PL3275438T3 (da)
PT (1) PT3275438T (da)
RS (1) RS61403B1 (da)
SI (1) SI3275438T1 (da)
SM (1) SMT202100035T1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2010241571B2 (en) 2009-04-29 2014-06-26 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
PL3318255T3 (pl) 2009-06-15 2021-09-06 Amarin Pharmaceuticals Ireland Limited Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
IL275396B2 (en) 2012-06-29 2024-11-01 Amarin Pharmaceuticals Ie Ltd Eicosapentaenoic acid and docosapentaenoic acid for use as a medicament for reducing a risk of cardiovascular death
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
CA3085951C (en) * 2017-12-21 2022-10-11 Kowa Company, Ltd. Methods of treatment of hypertriglyceridemia
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3791874A4 (en) * 2018-05-08 2022-02-23 National University Corporation Okayama University USEFUL MEDICINES FOR CARDIOVASCULAR DISEASES
JP2021534185A (ja) * 2018-08-17 2021-12-09 アマリン ファーマシューティカルズ アイルランド リミテッド スタチン治療対象における末梢動脈血行再建の必要性を低減する方法
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
JP7071538B2 (ja) * 2018-12-27 2022-05-19 興和株式会社 医薬組成物
EP3903781A4 (en) * 2018-12-27 2023-01-25 Kowa Company, Ltd. PHARMACEUTICAL PREPARATION
CA3056663C (en) * 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
JPWO2024014524A1 (da) * 2022-07-15 2024-01-18
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease
CN118873513B (zh) * 2024-08-13 2025-01-28 烟台大学 一种尼达尼布组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101160808B1 (ko) 2003-09-03 2012-06-29 코와 가부시키가이샤 Ｐｐａｒ 활성화 화합물 및 이를 함유하는 의약 조성물
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑

Also Published As

Publication number Publication date
ES2847168T5 (es) 2024-02-20
US20210069158A1 (en) 2021-03-11
US20210077467A1 (en) 2021-03-18
RS61403B1 (sr) 2021-02-26
LT3275438T (lt) 2021-03-25
SI3275438T1 (sl) 2021-05-31
PL3275438T3 (pl) 2021-05-17
ES2847168T3 (es) 2021-08-02
US20180028505A1 (en) 2018-02-01
SMT202100035T1 (it) 2021-03-15
US20210085652A1 (en) 2021-03-25
PT3275438T (pt) 2021-01-25
EP3275438A1 (en) 2018-01-31
US20180028506A1 (en) 2018-02-01
EP3791872A1 (en) 2021-03-17
HRP20210082T1 (hr) 2021-03-05
HUE053081T2 (hu) 2021-06-28
US10869859B2 (en) 2020-12-22
EP3275438B2 (en) 2023-09-13
CY1123833T1 (el) 2022-05-27
EP3275438B1 (en) 2020-10-28
US10864198B2 (en) 2020-12-15

Similar Documents

Publication Publication Date Title
DK3275438T3 (da) Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
DK3259386T3 (da) Systemer og fremgangsmåder til udførelse af immunoassays
DK3346629T3 (da) Fremgangsmåde og enhed til overførsel af informationer
DK3191809T3 (da) System og fremgangsmåde til fremstilling af en farmaceutisk forbindelse
DK3114540T3 (da) Neuralt netværk og fremgangsmåder til træning af neuralt netværk
DK3519572T5 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3122444T3 (da) Fremgangsmåde til fremstilling af membraner
DK3237578T3 (da) Fremgangsmåde og anordning til reduktion af tunge aromatiske polycikliske forbindelser i hydrokrakningsenheder
DK3126373T3 (da) Fremgangsmåde til fremstilling af amg 416
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3319948T3 (da) Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse
DK3274469T3 (da) Fremgangsmåder til detektering af en biologisk kontaminant
DK3322695T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3563733T3 (da) Fremgangsmåde til tilberedning af en drikkevare og en indretning til tilberedning af en drikkevare
DK3395024T3 (da) Fremgangsmåder og knuder til håndtering af bærere
DK3237169T3 (da) Fremgangsmåde til fremstilling af formdele og produkter
DK3319949T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3534709T3 (da) Substituerede sulfonylamider til bekæmpelse af skadedyr
DK3265443T3 (da) Pyrrolidincarboxamidderivater og fremgangsmåde til fremstilling og anvendelse af samme
DK3091882T3 (da) Fremgangsmåde og indretning til fremstilling af en drik
DK3304106T3 (da) Jævnstrømsmåler og fremgangsmåde til anvendelse deraf
DK3302829T3 (da) Indretning til sortering af genstande i sække
DK3285654T3 (da) Fremgangsmåde til udtagning af mikroorganismer, indretning til udtagning af mikroorganismer og sæt til udtagning med en sådan indretning til udtagning
DK3430072T3 (da) Fremgangsmåde til oprensning af poloxamerer